^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    beta-lapachone (ARQ 761)

    i
    Other names: ARQ 761
    Company:
    Merck (MSD)
    Drug class:
    NQO1 inhibitor
    4years
    β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. (PubMed, Front Oncol)
    β-Lapachone (ARQ761 in clinical form) selectively kill NADPH: quinone oxidoreductase 1 (NQO1)-overexpressing cancer cells...Our data suggest that NQO1 is an ideal potential biomarker, and relatively high NQO1:CAT ratios in HCC tumors but low ratios in normal tissues offer an optimal therapeutic window to use β-Lapachone. This study provides novel preclinical evidence for β-Lapachone as a new promising chemotherapeutic agent for use in NQO1-positive HCC patients.
    Journal • PARP Biomarker
    |
    NQO1 (NAD(P)H dehydrogenase, quinone 1) • CAT (Catalase)
    |
    NQO1 overexpression • NQO1 positive
    |
    beta-lapachone (ARQ 761)